Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 7 (2010), Issue 4 (April)

1. In vitro and in vivo photocytotoxicity of boron dipyrromethene derivatives for photodynamic therapy.
   J Med Chem, 53(7): 2865-74. [Abstract] [Full-text]
2. Multidimensional atomic force microscopy for drug discovery: a versatile tool for defining targets, designing therapeutics and monitoring their efficacy.
   Life Sci, 86(15): 545-62. [Abstract] [Full-text]
3. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
   Lancet Oncol, 11(4): 350-7. [Abstract] [Full-text]
4. Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer.
   Am J Surg, 199(4): 477-84. [Abstract] [Full-text]
5. Increased potency of the PHSCN dendrimer as an inhibitor of human prostate cancer cell invasion, extravasation, and lung colony formation.
   Clin Exp Metastasis, 27(3): 173-84. [Abstract] [Full-text]
6. A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS).
   Jpn J Clin Oncol, 40(4): 369-72. [Abstract] [Full-text]
7. Declining 1-year case-fatality of stroke and increasing coverage of vascular risk management: population-based cohort study.
   J Neurol Neurosurg Psychiatry, 81(4): 416-22. [Abstract] [Full-text]
8. Efficacy and feasibility of combination chemotherapy with S-1 and cisplatin (2 weeks regimen) for advanced gastric cancer.
   Jpn J Clin Oncol, 40(4): 302-6. [Abstract] [Full-text]
9. Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis.
   Jpn J Clin Oncol, 40(4): 360-4. [Abstract] [Full-text]
10. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.
    Jpn J Clin Oncol, 40(4): 286-93. [Abstract] [Full-text]
11. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Jpn J Clin Oncol, 40(4): 313-8. [Abstract] [Full-text]
12. A case with Hodgkin lymphoma and fronto-temporal lobular degeneration (FTLD)-like dementia facilitated by chemotherapy.
    Jpn J Clin Oncol, 40(4): 365-8. [Abstract] [Full-text]
13. Long-term follow-up results of breast cancer patients with sentinel lymph node biopsy using periareolar injection.
    Am J Surg, 199(4): 442-6. [Abstract] [Full-text]
14. A self-organized 3-diethylaminopropyl-bearing glycol chitosan nanogel for tumor acidic pH targeting: in vitro evaluation.
    Colloids Surf B Biointerfaces, 78(1): 120-6. [Abstract] [Full-text]
15. Clinical outcome of acute leg ischaemia due to thrombosed popliteal artery aneurysm: systematic review of 895 cases.
    Eur J Vasc Endovasc Surg, 39(4): 452-7. [Abstract] [Full-text]
16. Foam sclerotherapy of the saphenous veins: randomised controlled trial with or without compression.
    Eur J Vasc Endovasc Surg, 39(4): 500-7. [Abstract] [Full-text]
17. Randomised clinical trial of foam sclerotherapy for patients with a venous leg ulcer.
    Eur J Vasc Endovasc Surg, 39(4): 495-9. [Abstract] [Full-text]
18. Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial.
    Gynecol Oncol, 117(2): 276-80. [Abstract] [Full-text]
19. Investigation of archaeosomes as carriers for oral delivery of peptides.
    Biochem Biophys Res Commun, 394(2): 412-7. [Abstract] [Full-text]
20. Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines.
    Gynecol Oncol, 117(2): 202-10. [Abstract] [Full-text]
21. Race/ethnicity, quality of care, and outcomes in ischemic stroke.
    Circulation, 121(13): 1492-501. [Abstract] [Full-text]
22. Image-guided convection-enhanced delivery of muscimol to the primate brain.
    J Neurosurg, 112(4): 790-5. [Abstract] [Full-text]
23. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?
    J Natl Cancer Inst, 102(7): 456-63. [Abstract] [Full-text]
24. Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.
    Cancer Invest, 28(4): 408-12. [Abstract] [Full-text]
25. Single-dose versus multiple-dose antibiotic prophylaxis for the surgical treatment of closed fractures.
    Acta Orthop, 81(2): 258-64. [Abstract] [Full-text]
26. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
    N Engl J Med, 362(14): 1273-81. [Abstract] [Full-text]
27. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
    Nat Med, 16(4): 460-5. [Abstract] [Full-text]
28. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
    Am J Clin Oncol, 33(2): 144-7. [Abstract] [Full-text]
29. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules.
    Am J Clin Oncol, 33(2): 137-43. [Abstract] [Full-text]
30. Treatment of adult rhabdomyosarcoma.
    Am J Clin Oncol, 33(2): 128-31. [Abstract] [Full-text]
31. S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.
    Am J Clin Oncol, 33(2): 117-20. [Abstract] [Full-text]
32. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma.
    Am J Clin Oncol, 33(2): 121-4. [Abstract] [Full-text]
33. A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma.
    Am J Clin Oncol, 33(2): 111-6. [Abstract] [Full-text]
34. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy.
    Am J Clin Oncol, 33(2): 148-52. [Abstract] [Full-text]
35. Novel biodegradable composite wound dressings with controlled release of antibiotics: microstructure, mechanical and physical properties.
    J Biomed Mater Res B Appl Biomater, 93(2): 425-35. [Abstract] [Full-text]
36. In vitro antibacterial efficacy of tetracycline hydrochloride adsorbed onto Bio-Oss bone graft.
    J Biomed Mater Res B Appl Biomater, 93(2): 394-400. [Abstract] [Full-text]
37. Poly(vinyl alcohol) films for topical delivery of S-nitrosoglutathione: effect of freezing-thawing on the diffusion properties.
    J Biomed Mater Res B Appl Biomater, 93(2): 416-24. [Abstract] [Full-text]
38. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer.
    J Clin Oncol, 28(11): 1821-8. [Abstract] [Full-text]
39. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
    J Clin Oncol, 28(11): 1850-5. [Abstract] [Full-text]
40. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial.
    J Clin Oncol, 28(11): 1843-9. [Abstract] [Full-text]
41. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
    J Clin Oncol, 28(11): 1829-34. [Abstract] [Full-text]
42. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
    J Clin Oncol, 28(11): 1856-62. [Abstract] [Full-text]
43. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.
    J Clin Oncol, 28(11): 1911-8. [Abstract] [Full-text]
44. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
    J Clin Oncol, 28(11): 1863-9. [Abstract] [Full-text]
45. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
    J Clin Oncol, 28(11): 1835-42. [Abstract] [Full-text]
46. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
    J Clin Oncol, 28(11): 1896-903. [Abstract] [Full-text]
47. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.
    Blood, 115(14): 2755-62. [Abstract] [Full-text]
48. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.
    Blood, 115(14): 2740-8. [Abstract] [Full-text]
49. Compliance with antibiotic prophylaxis in children with vesicoureteral reflux: results from a national pharmacy claims database.
    J Urol, 183(5): 1994-9. [Abstract] [Full-text]
50. Advanced penile verrucous carcinoma treated with intra-aortic infusion chemotherapy.
    J Urol, 183(5): 1830-5. [Abstract] [Full-text]
51. The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines.
    Biochem Biophys Res Commun, 394(3): 760-6. [Abstract] [Full-text]
52. RLIP76: a versatile transporter and an emerging target for cancer therapy.
    Biochem Pharmacol, 79(12): 1699-705. [Abstract] [Full-text]
53. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
    Biomaterials, 31(17): 4748-56. [Abstract] [Full-text]
54. EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
    Br J Cancer, 102(8): 1235-43. [Abstract] [Full-text]
55. alpha-Tocopheryl succinate promotes selective cell death induced by vitamin K3 in combination with ascorbate.
    Br J Cancer, 102(8): 1224-34. [Abstract] [Full-text]
56. A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Cancer Chemother Pharmacol, 66(1): 191-5. [Abstract] [Full-text]
57. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice.
    Proc Natl Acad Sci U S A, 107(15): 7101-6. [Abstract] [Full-text]
58. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
    Cancer Chemother Pharmacol, 66(1): 181-9. [Abstract] [Full-text]
59. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Cancer Chemother Pharmacol, 66(1): 203-7. [Abstract] [Full-text]
60. "Metronomic" chemotherapy in advanced soft tissue sarcomas.
    Cancer Chemother Pharmacol, 66(1): 197-202. [Abstract] [Full-text]
61. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis.
    Cancer, 116(8): 1947-52. [Abstract] [Full-text]
62. Sensitivity of breast cancer cell lines to recombinant thiaminase I.
    Cancer Chemother Pharmacol, 66(1): 171-9. [Abstract] [Full-text]
63. The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study.
    Cancer Chemother Pharmacol, 66(1): 159-69. [Abstract] [Full-text]
64. Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancer.
    Cancer Chemother Pharmacol, 66(1): 107-12. [Abstract] [Full-text]
65. Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge.
    Cancer Chemother Pharmacol, 66(1): 113-20. [Abstract] [Full-text]
66. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Cancer Chemother Pharmacol, 66(1): 43-52. [Abstract] [Full-text]
67. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
    Cancer Chemother Pharmacol, 66(1): 151-8. [Abstract] [Full-text]
68. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
    Cancer Chemother Pharmacol, 66(1): 59-67. [Abstract] [Full-text]
69. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
    Cancer Chemother Pharmacol, 66(1): 95-105. [Abstract] [Full-text]
70. Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer.
    Cancer Chemother Pharmacol, 66(1): 89-94. [Abstract] [Full-text]
71. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer.
    Cancer Chemother Pharmacol, 66(1): 31-6. [Abstract] [Full-text]
72. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro.
    Cancer Chemother Pharmacol, 66(1): 21-9. [Abstract] [Full-text]
73. Liposomal pegylated doxorubicin and oxaliplatin as salvage chemotherapy in patients with metastatic gastric cancer treated earlier.
    Anticancer Drugs, 21(5): 559-64. [Abstract] [Full-text]
74. Triptolide circumvents drug-resistant effect and enhances 5-fluorouracil antitumor effect on KB cells.
    Anticancer Drugs, 21(5): 502-13. [Abstract] [Full-text]
75. Synthesis, biodistribution, and microsingle photon emission computed tomography (SPECT) imaging study of technetium-99m labeled PEGylated dendrimer poly(amidoamine) (PAMAM)-folic acid conjugates.
    J Med Chem, 53(8): 3262-72. [Abstract] [Full-text]
76. Randomized clinical trial of different bandage regimens after foam sclerotherapy for varicose veins.
    Br J Surg, 97(5): 650-6. [Abstract] [Full-text]
77. Complications of intravitreal injections.
    Curr Opin Ophthalmol, 21(3): 178-83. [Abstract] [Full-text]
78. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
    Blood, 115(15): 3017-24. [Abstract] [Full-text]
79. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
    Blood, 115(15): 3008-16. [Abstract] [Full-text]
80. Macromolecular drug transport into the brain using targeted therapy.
    J Neurochem, 113(1): 1-13. [Abstract] [Full-text]
81. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
    Int J Radiat Oncol Biol Phys, 77(1): 9-15. [Abstract] [Full-text]
82. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.
    Int J Radiat Oncol Biol Phys, 77(1): 79-85. [Abstract] [Full-text]
83. Listen carefully: the risk of error in spoken medication orders.
    Soc Sci Med, 70(10): 1599-608. [Abstract] [Full-text]
84. Hypothesis: upfront use of ABL kinase inhibitor combination, either simultaneously or sequentially, in high-risk Ph+ leukemias?
    Ann Hematol, 89(6): 531-3. [Abstract] [Full-text]
85. Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.
    Ann Hematol, 89(6): 563-8. [Abstract] [Full-text]
86. Overexpression of the drug resistance-associated protein metallothionein does not correlate with response of sarcomas to isolated limb perfusion treatment.
    J Surg Oncol, 101(6): 465-70. [Abstract] [Full-text]
87. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center.
    J Surg Oncol, 101(6): 457-64. [Abstract] [Full-text]
88. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
    J Clin Oncol, 28(12): 2077-84. [Abstract] [Full-text]
89. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
    J Clin Oncol, 28(12): 2015-23. [Abstract] [Full-text]
90. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    J Clin Oncol, 28(12): 2024-31. [Abstract] [Full-text]
91. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
    J Clin Oncol, 28(12): 2070-6. [Abstract] [Full-text]
92. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.
    J Clin Oncol, 28(12): 2058-63. [Abstract] [Full-text]
93. Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy.
    Int J Cancer, 126(12): 2935-46. [Abstract] [Full-text]
94. Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria.
    Int J Antimicrob Agents, 35(6): 553-8. [Abstract] [Full-text]
95. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
    Pediatr Blood Cancer, 54(7): 909-15. [Abstract] [Full-text]
96. Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL).
    Pediatr Blood Cancer, 54(7): 934-40. [Abstract] [Full-text]
97. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.
    Pediatr Blood Cancer, 54(7): 872-8. [Abstract] [Full-text]
98. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.
    J Natl Cancer Inst, 102(8): 522-8. [Abstract] [Full-text]
99. The need for precompetitive integrative bionetwork disease model building.
    Clin Pharmacol Ther, 87(5): 536-9. [Abstract] [Full-text]
100. Targeted cancer therapies in the twenty-first century: lessons from imatinib.
     Clin Pharmacol Ther, 87(5): 543-52. [Abstract] [Full-text]
101. Accuracy and precision of intravitreally injected ranibizumab doses: an experimental study.
     Klin Monbl Augenheilkd, 227(4): 269-72. [Abstract] [Full-text]
102. Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma.
     J Cancer Res Clin Oncol, 136(6): 883-9. [Abstract] [Full-text]
103. The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.
     J Cancer Res Clin Oncol, 136(6): 803-9. [Abstract] [Full-text]
104. Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
     J Thorac Cardiovasc Surg, 139(5): 1224-32, 1232.e1. [Abstract] [Full-text]
105. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
     J Thorac Cardiovasc Surg, 139(5): 1233-40. [Abstract] [Full-text]
106. Postexposure prophylaxis for HIV.
     Emerg Med Clin North Am, 28(2): 421-9, Table of Contents. [Abstract] [Full-text]
107. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.
     Blood, 115(16): 3206-14. [Abstract] [Full-text]
108. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
     Blood, 115(16): 3215-23. [Abstract] [Full-text]
109. Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era.
     J Acquir Immune Defic Syndr, 54(1): 78-84. [Abstract] [Full-text]
110. The link between intravenous multiple pump flow errors and infusion system mechanical compliance.
     Anesth Analg, 110(5): 1297-302. [Abstract] [Full-text]
111. Outcomes of HIV-exposed children in western Kenya: efficacy of prevention of mother to child transmission in a resource-constrained setting.
     J Acquir Immune Defic Syndr, 54(1): 42-50. [Abstract] [Full-text]
112. Failure of highly active antiretroviral therapy in reconstituting immune response to Clostridium tetani vaccine in aged AIDS patients.
     J Acquir Immune Defic Syndr, 54(1): 10-7. [Abstract] [Full-text]
113. Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa.
     J Acquir Immune Defic Syndr, 54(1): 35-41. [Abstract] [Full-text]
114. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study.
     J Acquir Immune Defic Syndr, 54(1): 27-34. [Abstract] [Full-text]
115. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.
     J Acquir Immune Defic Syndr, 54(1): 63-70. [Abstract] [Full-text]
116. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006.
     J Acquir Immune Defic Syndr, 54(1): 71-7. [Abstract] [Full-text]
117. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.
     Cancer, 116(9): 2180-7. [Abstract] [Full-text]
118. The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
     Cancer, 116(9): 2208-14. [Abstract] [Full-text]
119. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy.
     Cancer, 116(9): 2099-105. [Abstract] [Full-text]
120. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.
     Cancer, 116(9): 2081-9. [Abstract] [Full-text]
121. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer.
     Cancer, 116(9): 2132-9. [Abstract] [Full-text]
122. Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases.
     Cancer, 116(9): 2106-14. [Abstract] [Full-text]
123. Thyroxine replacement during super-ovulation for in vitro fertilization: a potential gap in management?
     Fertil Steril, 93(7): 2414.e1-3. [Abstract] [Full-text]
124. Treatment of osteomyelitis with teicoplanin-encapsulated biodegradable thermosensitive hydrogel nanoparticles.
     Biomaterials, 31(19): 5227-36. [Abstract] [Full-text]
125. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate.
     Biomaterials, 31(19): 5258-65. [Abstract] [Full-text]
126. The attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase.
     Biomaterials, 31(19): 5218-26. [Abstract] [Full-text]
127. Accelerated Achilles tendon healing by PDGF gene delivery with mesoporous silica nanoparticles.
     Biomaterials, 31(19): 5237-45. [Abstract] [Full-text]
128. Slow-release nanoparticle-encapsulated delivery system for laryngeal injection.
     Laryngoscope, 120(5): 988-94. [Abstract] [Full-text]
129. Association of interruptions with an increased risk and severity of medication administration errors.
     Arch Intern Med, 170(8): 683-90. [Abstract] [Full-text]
130. Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity.
     J Vasc Surg, 51(5): 1209-14. [Abstract] [Full-text]
131. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study.
     Stroke, 41(5): 885-90. [Abstract] [Full-text]
132. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?
     Acta Obstet Gynecol Scand, 89(5): 623-8. [Abstract] [Full-text]
133. Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia.
     Am J Hematol, 85(5): 325-30. [Abstract] [Full-text]
134. Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer.
     Br J Cancer, 102(9): 1341-7. [Abstract] [Full-text]
135. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
     Br J Cancer, 102(9): 1355-60. [Abstract] [Full-text]
136. Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.
     Cancer Immunol Immunother, 59(7): 1073-81. [Abstract] [Full-text]
137. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.
     Cancer Immunol Immunother, 59(7): 1001-9. [Abstract] [Full-text]
138. Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice.
     Radiat Res, 173(5): 590-601. [Abstract] [Full-text]
139. Alzheimer's disease: strategies for disease modification.
     Nat Rev Drug Discov, 9(5): 387-98. [Abstract] [Full-text]
140. Teaching old receptors new tricks: biasing seven-transmembrane receptors.
     Nat Rev Drug Discov, 9(5): 373-86. [Abstract] [Full-text]
141. Personalized medicine in oncology: the future is now.
     Nat Rev Drug Discov, 9(5): 363-6. [Abstract] [Full-text]
142. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.
     J Clin Oncol, 28(13): 2233-8. [Abstract] [Full-text]
143. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
     J Clin Oncol, 28(13): 2227-32. [Abstract] [Full-text]
144. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.
     J Clin Oncol, 28(13): 2246-52. [Abstract] [Full-text]
145. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
     J Clin Oncol, 28(13): 2239-45. [Abstract] [Full-text]
146. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
     J Clin Oncol, 28(13): 2259-66. [Abstract] [Full-text]
147. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
     J Clin Oncol, 28(13): 2131-6. [Abstract] [Full-text]
148. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
     J Clin Oncol, 28(13): 2137-43. [Abstract] [Full-text]
149. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
     J Clin Oncol, 28(13): 2144-50. [Abstract] [Full-text]
150. Role of adjuvant therapy after resection of colorectal cancer liver metastases.
     J Clin Oncol, 28(13): 2300-9. [Abstract] [Full-text]
151. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.
     J Clin Oncol, 28(13): 2167-73. [Abstract] [Full-text]
152. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
     J Clin Oncol, 28(13): 2213-9. [Abstract] [Full-text]
153. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.
     J Clin Oncol, 28(13): 2191-7. [Abstract] [Full-text]
154. Interruptions during the delivery of high-risk medications.
     J Nurs Adm, 40(5): 211-8. [Abstract] [Full-text]
155. African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy.
     J Infect Dis, 201(11): 1703-7. [Abstract] [Full-text]
156. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
     Cancer Res, 70(9): 3606-17. [Abstract] [Full-text]
157. Computed tomography guided intra-articular injection of etanercept in the sacroiliac joint is an effective mode of treatment of ankylosing spondylitis.
     Scand J Rheumatol, 39(3): 229-32. [Abstract] [Full-text]
158. Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
     J Cell Physiol, 224(1): 112-9. [Abstract] [Full-text]
159. Prevalence of ADHD diagnosis and nonmedical prescription stimulant use in medical students.
     Acad Psychiatry, 34(3): 220-3. [Abstract] [Full-text]
160. Distribution of doxorubicin in rats undergoing ultrasonic drug delivery.
     J Pharm Sci, 99(7): 3122-31. [Abstract] [Full-text]
161. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs.
     J Pharm Sci, 99(7): 3072-80. [Abstract] [Full-text]
162. Release liner removal method for transdermal drug delivery systems (TDDS).
     J Pharm Sci, 99(7): 3177-87. [Abstract] [Full-text]
163. Examination of the ability of the nasal administration route to confer a brain exposure advantage for three chemical inhibitors of P-glycoprotein.
     J Pharm Sci, 99(7): 3226-33. [Abstract] [Full-text]
164. Development of mucoadhesive films for buccal administration of flufenamic acid: Effect of cyclodextrin complexation.
     J Pharm Sci, 99(7): 3019-29. [Abstract] [Full-text]
165. Determination of water penetration and drug concentration profiles in HPMC-based matrix tablets by near infrared chemical imaging.
     J Pharm Sci, 99(7): 3081-8. [Abstract] [Full-text]
166. Drug release from irradiated PLGA and PLLA multi-layered films.
     J Pharm Sci, 99(7): 3060-71. [Abstract] [Full-text]
167. Amphiphilic cyclodextrins as nanocarriers of genistein: A spectroscopic investigation pointing out the structural properties of the host/drug complex system.
     J Pharm Sci, 99(7): 3141-9. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.